083790.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 liep. 2024 @ 09:01):
Our systems believe the stock currently is undervalued by 0.02% compare to its pairs and should correct upwards.

Stats
Dzisiejszy wolumen	114 003
Średni wolumen	199 147
Kapitalizacja rynkowa	207.83B
EPS	KRW-98.15 ( Q1 \| 2024-03-31 )
Następna data zysków	( KRW0 ) 2024-08-14
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW4.70 (0.17%)

Korelacja (AI algo v.1.1b): Undervalued: 0.02% KRW2 800.59 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.07 (neutral)

Krótki: 0.30 (neutral)

Signal:(56.225) Neutral

CrystalGenomics, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CrystalGenomics, Inc. Korelacja - Waluta/Towar

-0.71
( moderate negative )

-0.56
( weak negative )

-0.48
( neutral )

0.32
( neutral )

0.64
( weak )

CrystalGenomics, Inc. Finanse

Annual	2023
Przychody:	KRW4.88B
Zysk brutto:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Przychody:	KRW4.88B
Zysk brutto:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Przychody:	KRW17.46B
Zysk brutto:	KRW9.07B (51.96 %)
EPS:	KRW132.36

FY	2022
Przychody:	KRW16.25B
Zysk brutto:	KRW8.47B (52.13 %)
EPS:	KRW117.19

Financial Reports:

No articles found.

CrystalGenomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.